Table 3.

Probabilistic Cost-effectiveness Analyses, Comparing the Trial Arms in Terms of Mean Total Health Care Costs and Death Rate (%)

	Total Cost per Patient and Death Rate (%) Per Arm		Incremental Comparison of 1 Week of AmB and 5FC Versus 2 Weeks of FLU and 5FC
ACTA Treatment Arms	Mean Total Costs	Deaths (%)	Incremental Costs per Patient	Incremental Death Rate (%)	Incremental Costs Per Life-year Saved
2 weeks of oral FLU and 5FC	1442 (1336–1565)	35 (28–41)	Reference	Reference	Reference
1 week of AmB and FLU	1763 (1567–1979)	49 (39–58)	...	...	...
1 week of AmB and 5FC	1861 (1724–2033)	24 (16–31)	419 (236–619)	11 (0.6–21)	208 (91–1210)
2 weeks of AmB and FLU	2125 (1946–2313)	41 (32–49)	...	...	...
2 weeks of AmB and 5FC (Comparator)	2285 (2070–2525)	38 (29–46)	...	...	...

Compared to other treatment combinations, 2 weeks of oral treatment and 1 week of AmB and 5FC showed lower costs and better health outcomes (ie, cost less and averted more deaths). In economic terms, these 2 treatments dominate the other options. The incremental cost-effectiveness is shown for these remaining favorable options on the right half of the table. The average estimated life expectancy is 18 years, as reported in Rajasingham et al’s study [11]. The numbers in parentheses are estimates of the 95% confidence intervals, as estimated by boot-strapping. Abbreviations: 5FC, flucytosine; AmB, amphotericin B; FLU, fluconazole.